drugset
drugset / Trial / NCT02313883

A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT02313883 ↗

Phase 1/2 Completed 127 enrolled Geistlich Pharma AG
RandomizedParallel-groupSingle-blindTreatment

Summary

A Pharmacokinetic Pilot followed by a Phase I/II, Blinded, Randomized, Controlled, Parallel Arm Trial to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects with Periodontitis

Timeline

Start
2015-07
Primary completion
2018-07-02
Completion
2018-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject taurolidine Small molecule 0.3 % Other
Subject taurolidine Small molecule 1 % Other
Subject taurolidine Small molecule 3 % Other

Indications

periodontitis